[1] DAS K, BAUMAN J, CLARK A, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations . Proc Natl Acad Sci, 2008, 105: 1466-1471.[2] CRAUWELS H, VINGERHOETS J, RYAN R, et al. Pharmaconetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects . Antivir Ther, 2012,17(3):439-446.[3] DE BETHUNE M, ANDRIES K, AZIJN H, et al. TMC-278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile . 12th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005, Boston, MA.[4] DICKINSON L, KHOO S, BACK D. Pharmacokinetics and drug-drug interactions of antiretrovirals: An update . Antiviral Res, 2010,85(1):176-189.[5] JAYAWEERA D, DILANCHIAN P. RILPIVIRINE. First-line treatment of HIV infection: Efavirenz is better documented . Prescrire Int, 2012, 21(132):262-265.[6] COHEN C J, ANDRADE-VILLANUEVA J, CLOTET B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial . Lancet, 2011, 378(9787):229-237.[7] COHEN C J, MOLINA J M, CASSETTI I, et al. Week 96 efficacy and safety of rilpivirine in treatment-na ve, HIV-1 patients in two phase III randomised trials . AIDS, 2012, 14(3):168-178.[8] SHARMA M, SARAVOLATZ L D. Rilpivirine: A new non-nucleoside reverse transcriptase inhibitor . J Antimicrob Chemoth, 2012, 55(2):107-113. [9] NIMISH PATEL, CHRISTOPHER D MILLER. New option for management of HIV-1 infection in treatment-naive patients: Once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir . HIV AIDS (Auckl), 2012, 4: 61-71. CALVIN J. COHEN, JEAN-MICHEL MOLINA, PEDRO CAHN, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials . Clin Sci, 2012, 60(1):33-42. MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, et al. ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial . Lancet, 2011, 378(9787):238-246. BUNUPURADAH T, ANANWORANICH J, CHETCHOTISAKD P,, et al. Etravirine and ripilvirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. Antivir Ther, 2011, 16(7):1113-1121. CRAUWELS H, WILLIAMS P, BOVEN K, et al. TMC278 drug-drug interactions: An overview . 4th Annual American Conference for the Treatment of HIV (ACTHIV); 7-9 April 2011, Denver, CO, USA. JULIETA D AZ-DELF N, PERE DOMINGO, MARIA GRACIA MATEO, et al. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines . Antimicrob Agents Ch, 2012, 56(6):3369-3375. DANIEL A. HUSSAR, CLAYTON W. SNELL. Boceprevir, telaprevir, and rilpivirine hydrochloride . J Am Pharm Assoc, 2012, 52(1):120-126. MARK NELSON1, GERARDO AMAYA, NATHAN CLUMECK, et al. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials . J Antimicrob Chemoth, 2012, 4(24):1-9.